LOXO Oncology Annual Revenue, Number of Employees, Growth and Funding
Navigation
Overview
Industry Ranking
State Ranking
Estimated Revenue & Financials
- LOXO Oncology's estimated annual revenue is currently $31.4M per year.
- LOXO Oncology received $294.8M in venture funding in June 2017.
- LOXO Oncology's estimated revenue per employee is $201,000
- LOXO Oncology's total funding is $125.3M.
Employee Data
- LOXO Oncology has 156 Employees.
- LOXO Oncology grew their employee count by 73% last year.
- LOXO Oncology currently has 6 job openings.
Executive Contacts
| Name | Title |
|---|---|
| Steven Andrews | Vice President, Discovery Chemistry |
| Nisha Nanda | VP Development Strategy |
| Sara Slifka | Sara Slifka VP, Business Operations & Program Management |
| Jonathan Katchmore | Director, Diagnostic Account Strategy |
| Cindy Adduci | Senior Director Program Management |
| Stacey Spencer | Associate Director, Cmc |
| Christine Schrade | Executive Assistant Office Manager |
| Mary Rosendahl | Principal Research Scientist |
| Kristin Hopp | Biospecimen Manager |
| Narasimha Marella | Director, Biomarker Operations |
What Is LOXO Oncology?
Loxo Oncology is a biopharmaceutical company dedicated to developing highly-selective medicines for patients with genomically defined cancers. Our pipeline is focused on treatments aimed at cancers caused by a single inappropriate DNA change, known as oncogenic drivers, which the tumor depends on for growth and survival. Loxo Oncology develops purpose-built medicines designed to selectively and potently inhibit these oncogenic drivers. We believe that this approach, combined with the use of tumor genomic testing to identify appropriate patients, will allow us to develop medicines that provide best-in-class disease control and safety and, ultimately, deliver on the promise of precision medicine. We are based in Stamford, CT with sites in San Francisco, CA and Boulder, CO. For more information about Loxo Oncology, please visit us at www.loxooncology.com.
keywords:Biotechnology,Healthcare,Pharmaceuticals156
Number of Employees
$31.4M
Revenue (est)
6
Current Jobs
73%
Employee Growth %
$125.3M
Total Funding
N/A
Valuation
N/A
Accelerator
B2B
Type
Similar Companies
| Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
| $6.8M | 34 | 6% | N/A | |
| $6.2M | 31 | N/A | N/A | |
| $21.9M | 109 | 11% | N/A | |
| $144.3M | 718 | 27% | N/A | |
| $31.4M | 156 | 73% | N/A | |
| $13.1M | 65 | 8% | N/A |
LOXO Oncology News
Developed by Eli Lilly and Co's Loxo Oncology and marketed by ... with oncologists and pharmaceutical and diagnostic industry executives.
One example is the drug Vitrakvi, developed by Eli Lilly and its Loxo Oncology, which is marketed by Bayer. Vitrakvi works on cancers where ...
The bigger the book-to-market ratio is, the more fundamentally cheap is the investigated company. Loxo Oncology, Inc. (LOXO) has a BTM ratio ...
LOXO Oncology Funding
| Date | Amount | Round | Lead Investors | Reference |
|---|---|---|---|---|
| 2014-05-07 | $24.0M | B | New Enterprise Associates | Article |
| 2017-06-22 | $294.8M | Undisclosed | Morgan Stanley | Article |
LOXO Oncology Executive Hires
| Date | Name | Title | Reference |
|---|---|---|---|
| 2014-05-07 | Mikel Moyer | Chief Scientific Officer | Article |
| 2014-10-29 | Jennifer Low | Chief Medical Officer/EVP R/D | Article |